Risk factors for venous thromboembolism in severe COVID-19: a study-level meta-analysis of 21 studies
Venous thromboembolism (VTE) in patients with COVID-19 in intensive care units (ICU) is
frequent, but risk factors (RF) remain unidentified. In this meta-analysis (CRD42020188764) …
frequent, but risk factors (RF) remain unidentified. In this meta-analysis (CRD42020188764) …
Venous thromboembolism in COVID-19: A systematic review and meta-analysis
A Kollias, KG Kyriakoulis, S Lagou… - Vascular …, 2021 - journals.sagepub.com
Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of venous
thromboembolism events (VTE). This study performed a systematic review in …
thromboembolism events (VTE). This study performed a systematic review in …
Incidence and outcomes of thrombotic events in symptomatic patients with COVID-19
A Elbadawi, IY Elgendy, A Sahai… - … , and vascular biology, 2021 - Am Heart Assoc
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
(SARS-CoV-2) is associated with a heightened risk of thrombotic events. 1 We sought to …
(SARS-CoV-2) is associated with a heightened risk of thrombotic events. 1 We sought to …
Incidence of venous thromboembolism in hospitalized coronavirus disease 2019 patients: a systematic review and meta-analysis
C Zhang, L Shen, KJ Le, MM Pan, LC Kong… - Frontiers in …, 2020 - frontiersin.org
Background: Emerging evidence shows that coronavirus disease 2019 (COVID-19) is
commonly complicated by coagulopathy, and venous thromboembolism (VTE) is considered …
commonly complicated by coagulopathy, and venous thromboembolism (VTE) is considered …
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study
F Rashidi, S Barco, F Kamangar, GA Heresi… - Thrombosis research, 2021 - Elsevier
Background Thrombosis and pulmonary embolism appear to be major causes of mortality in
hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have …
hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have …
Proximal deep vein thrombosis and pulmonary embolism in COVID-19 patients: a systematic review and meta-analysis
G Longchamp, S Manzocchi-Besson, A Longchamp… - Thrombosis …, 2021 - Springer
Background COVID-19 appears to be associated with a high risk of venous
thromboembolism (VTE). We aimed to systematically review and meta-analyze the risk of …
thromboembolism (VTE). We aimed to systematically review and meta-analyze the risk of …
Comparison of venous thromboembolism risks between COVID-19 pneumonia and community-acquired pneumonia patients
F Mei, J Fan, J Yuan, Z Liang, K Wang… - … , and vascular biology, 2020 - Am Heart Assoc
Objective: The objectives were to investigate and compare the risks and incidences of
venous thromboembolism (VTE) between the 2 groups of patients with coronavirus disease …
venous thromboembolism (VTE) between the 2 groups of patients with coronavirus disease …
Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: a systematic review with meta-analysis
Background: A high incidence of venous thromboembolism (VTE) is reported in hospitalized
COVID-19 patients, in particular in patients admitted to the intensive care unit (ICU). In …
COVID-19 patients, in particular in patients admitted to the intensive care unit (ICU). In …
Venous thromboembolism in COVID-19: towards an ideal approach to thromboprophylaxis, screening, and treatment
Abstract Purpose of Review Novel coronavirus disease 2019 (COVID-19) has been
associated with an increased risk of arterial and venous thromboembolic (VTE) diseases …
associated with an increased risk of arterial and venous thromboembolic (VTE) diseases …
Association of AZD1222 and BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic events in frontline personnel: a retrospective cohort study
A Hviid, JV Hansen, EM Thiesson… - Annals of internal …, 2022 - acpjournals.org
Background: In March 2021, several European countries suspended the use of the
AZD1222 (Oxford–AstraZeneca) COVID-19 vaccine because of thromboembolic safety …
AZD1222 (Oxford–AstraZeneca) COVID-19 vaccine because of thromboembolic safety …